Lawrence Leung
Publications
- Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. J Biol Chem. 2013; (5): 3097-111
- Chemerin158K protein is the dominant chemerin isoform in synovial and cerebrospinal fluids but not in plasma. J Biol Chem. 2011; (45): 39520-7
- Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest. 2011; (9): 3517-27
- Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma. J Biol Chem. 2011; (45): 39510-9
- Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice. Arterioscler Thromb Vasc Biol. 2010; (7): 1363-70
- Heparin-induced thrombosis without thrombocytopenia. J Thorac Cardiovasc Surg. 2010; (2): e6-7
- What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost. 2010; (5): 868-76
- Proteolytic regulatory mechanism of chemerin bioactivity. Acta Biochim Biophys Sin (Shanghai). 2009; (12): 973-9
- Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem. 2009; (2): 751-8
- Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum. 2009; (10): 2902-12
- Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Adv Exp Med Biol. 2008: 61-9
- Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol. 2008; (16): 4080-3
- Thrombin hydrolysis of human osteopontin is dependent on thrombin anion-binding exosites. J Biol Chem. 2008; (26): 17789-96
- Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina? Am Heart J. 2007; (6): 1059-64
- Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood. 2007; (5): 1992-7
- Perioperative evaluation of bleeding diathesis. Hematology Am Soc Hematol Educ Program. 2006: 457-61
- Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery. J Biol Chem. 2004; (25): 26387-94
- Molecular cloning of nonsecreted endothelial cell-derived lipase isoforms. Genomics. 2004; (1): 24-33
- Molecular mapping of the thrombin-heparin cofactor II complex. J Biol Chem. 2004; (41): 43237-44
- Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem. 2003; (51): 51059-67
- Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. J Biol Chem. 2003; (48): 48112-9
- Structural requirements for the activation of human factor VIII by thrombin. Blood. 2002; (8): 2820-6
- An extensive interaction interface between thrombin and factor V is required for factor V activation. J Biol Chem. 2001; (27): 25143-9
- Identification of critical residues on thrombin mediating its interaction with fibrin. Thromb Haemost. 2001; (6): 1466-74
- Dissociation of thrombin's substrate interactions using site-directed mutagenesis. Trends Cardiovasc Med. 2000; (2): 89-92
- Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. J Biol Chem. 1999; (36): 25510-6
- A woman who had a stroke, then a myocardial infarction. Lancet. 1997; (9060): 1218
- Modulation of thrombin's procoagulant and anticoagulant properties. Thromb Haemost. 1997; (1): 577-80
- Strategies for development of novel antithrombotics: modulating thrombin's procoagulant and anticoagulant properties. Cell Mol Life Sci. 1997; (9): 731-6
- Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs. Thromb Haemost. 1995; (1): 373-6
- Conversion of thrombin into an anticoagulant by protein engineering Nature. 1995
- Functional mapping of the surface residues of human thrombin. J Biol Chem. 1995; (28): 16854-63
- Involvement of CD31 in lymphocyte-mediated immune responses: importance of the membrane-proximal immunoglobulin domain and identification of an inhibiting CD31 peptide. Blood. 1995; (5): 1282-8
- Selection of a suppressor mutation that restores affinity of an oligonucleotide inhibitor for thrombin using in vitro genetics. J Biol Chem. 1995; (33): 19370-6
- Identification of SVTCG as the conformation-dependent high affinity binding site in thrombospondin for its ligand CD36 J. Biol. Chem. 1994
- L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb. 1994; (10): 1529-33
- Identification of SVTCG in thrombospondin as the conformation-dependent, high affinity binding site for its receptor, CD36. J Biol Chem. 1993; (22): 16179-84
Help
Trial Administration